Triptans (Serotonin, 5-HT1B/1D Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials

@article{Ferrari2002Triptans5,
  title={Triptans (Serotonin, 5-HT1B/1D Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials},
  author={M. Ferrari and P. Goadsby and K. Roon and R. Lipton},
  journal={Cephalalgia},
  year={2002},
  volume={22},
  pages={633 - 658}
}
The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine drugs. [...] Key Method We asked pharmaceutical companies and the principal investigators of company-independent trials for the ‘raw patient data’ of all double-blind, randomized, controlled, clinical trials with oral triptans in migraine. All data were cross-checked with published or presented data.Expand
Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials
BACKGROUND The triptans, selective serotonin 5-HT(1B/1D) agonists, are very effective acute migraine drugs with a well- developed scientific rationale. Seven different triptans will soon beExpand
A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine
  • J. Pascual
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2004
TLDR
Control head-to-head data and a meta-analysis of 53 randomised, placebo-controlled trials of oral triptans in > 24,000 patients have shown that rizatriptan 10 mg offers efficacy advantages over oral sumatripta 50 and 100 mg and other oral triPTans, both in terms of speed of onset of action and consistency. Expand
Double-Blind Clinical Trials of Oral Triptans Vs Other Classes of Acute Migraine Medication — A Review
TLDR
It is found that experience in clinical practice suggests that, for many patients, oral triptans are superior to non-specific acute treatments, creating a discrepancy between clinical trials results and clinical practice experience. Expand
Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
TLDR
Oral lasmiditan seems to be safe and effective in the acute treatment of migraine and further assessment in larger placebo-controlled and triptan-controlled trials are needed. Expand
Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine
TLDR
Positive efficacy, safety and tolerability data has been reported for all gepants currently in clinical use or development, and these drugs offer an entirely novel class of treatment for migraine. Expand
Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment.
TLDR
The development of agents targeting the 5-HT1B/1D and 5- HT1F receptors and the clinical evidence supporting the use of these agents for acute migraine treatment are summarized. Expand
New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors
TLDR
Results from studies with BI 44370 TA do not support broad concern about a class effect, and further studies are ongoing in this respect, suggesting that iNOS is very unlikely to be a promising target. Expand
Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials
TLDR
The use of ubrogepant as an acute treatment of episodic migraine in adults led to a greater percentage of freedom from pain and absence of the most bothersome symptoms at 2 h post-dose and was not related to an increased risk for adverse events. Expand
Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs
TLDR
None of these reviewed treatments are likely to fulfill patients' expectations, and the advancement of acute migraine drugs should likely depend on different mechanisms from current 5-HT-related drugs. Expand
Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials
TLDR
In this meta-analysis, the use of lasmiditan as an acute treatment for episodic migraine in adults led to a greater percentage of freedom of pain and the absence of the most bothersome symptoms at 2 h post-dose. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 162 REFERENCES
311C90, A new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine
TLDR
Oral 311C90 (5 and 25 mg) is highly effective and well tolerated in the acute treatment of migraine and the response rates and treatment differences compared with placebo suggest possible superiority over existing antimigraine therapies. Expand
Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials
BACKGROUND The triptans, selective serotonin 5-HT(1B/1D) agonists, are very effective acute migraine drugs with a well- developed scientific rationale. Seven different triptans will soon beExpand
Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study
TLDR
The dose response data suggest that lower doses of oral zolmitriptan would also offer significant efficacy, and the most commonly reported adverse events were asthenia, dizziness, paraesthesia and feelings of heaviness. Expand
311C90: Long-term efficacy and tolerability profile for the acute treatment of migraine
TLDR
The efficacy profile and the nature/incidence of adverse events reported appear to be consistent with previous 311C90 studies, and the dosing regimen was well tolerated during multiple exposures. Expand
The Long‐term Tolerability and Efficacy of Oral Zolmitriptan (Zomig, 31X90) in the Acute Treatment of Migraine. An International Study
This international open‐label study evaluated the tolerability and efficacy of zolmitriptan (Zomig®, 311C90), a selective 5‐HT1B/1D receptor agonist in the long‐term treatment of multiple migraineExpand
311C90 (Zolmitriptan), A Novel Centrally and Peripheral Acting Oral 5-Hydroxytryptamine-1D Agonist: A Comparison of Its Absorption During A Migraine Attack and in A Migraine-Free Period
The oral absorption of a 10-m. oral dose of the novel 5-hydroxytryptamine (5HT1D) agonist, 311C90, was compared during a moderate or severe migraine headache and in a migraine-free period in an open,Expand
Headache after frequent use of serotonin agonists zolmitriptan and naratriptan
TLDR
There is evidence now that all members of the triptan family are able to cause drug-induced headache, and the weekly dosages necessary to initiate drug- induced headache with new highly effective 5HT agonists are lower than initially thought. Expand
Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group.
TLDR
The antimigraine effect of 10- and 20-mg rizatriptan was superior to placebo, and comparable with that of 100-mg sum atriptan succinate, although it was associated with a high frequency of adverse events. Expand
Double-Blind, Placebo-Controlled, Dose-Finding Study of Rizatriptan (MK-462) in the Acute Treatment of Migraine
TLDR
Patients who took rizatriptan 5 mg and 10 mg were significantly less functionally disabled than those who took placebo at 1.5 and 2n post-dose, and riz atriptan 10 mg was consistently more effective than 5 mg, although the differences were not statistically significant. Expand
Efficacy and Adverse Events of Subcutaneous, Oral, and Intranasal Sumatriptan Used for Migraine Treatment: A Systematic Review Based on Number Needed To Treat
  • P. Tfelt-Hansen
  • Medicine
  • Cephalalgia : an international journal of headache
  • 1998
TLDR
Therapeutic gain analysis during the first 2 h showed that subcutaneous sumatriptan was the fastest-acting form of administration, and this form in a dose of 6 mg is significantly more efficacious than 100 mg of oral sum atriptan, but causes more adverse events than oral sumAtriptan. Expand
...
1
2
3
4
5
...